← Back to Clinical Trials
Recruiting NCT07258875

NCT07258875 Effect of VExUS Ultrasound Protocol (Venous Excess Ultrasound) on Perioperative Fluid Management, on the Incidence of Postoperative Pulmonary Complications and Postoperative Acute Kidney Injury in Patients Undergoing Thoracic Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07258875
Status Recruiting
Phase
Sponsor University of Crete
Condition Thoracic Surgery With One-lung Ventilation
Study Type INTERVENTIONAL
Enrollment 230 participants
Start Date 2024-11-27
Primary Completion 2028-11-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Venous Excess UltrasoundStandard of Care (SOC)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 230 participants in total. It began in 2024-11-27 with a primary completion date of 2028-11-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to investigate the effect of a VExUS ultrasound guided protocol of perioperative fluid management within a goal-directed therapy framework, on postoperative respiratory complications, and the occurrence of acute kidney injury (AKI) in patients undergoing thoracic surgery.

Eligibility Criteria

Inclusion Criteria: * Adults \>18 years undergoing video assisted thoracic surgery/ lobectomy requiring one-lung ventilation. Exclusion Criteria: * Refusal to participate. * Pneumonectomy. * Young athletes (risk of physiologically large IVC \>2 cm). * Moderate-severe tricuspid regurgitation, moderate to severe pulmonary hypertension * Heart failure with reduced ejection fraction, EF\<35% * Portal hypertension, portal vein thrombosis, or liver cirrhosis. * Stage 4 or end-stage chronic kidney disease (eGFR \<30 mL/min/1.73 m² or dialysis). * Transfusion with more than 2 packed red blood cells unit perioperatively (intraoperatively, in the PACU, in the ward)

Contact & Investigator

Central Contact

Alexandros Bogas Manouselis, Resident of Anaesthesiology

✉ bogas.alexandros@gmail.com

📞 +306947545446

Principal Investigator

Alexandra Papaioannou, Professor of Anaesthesiology

STUDY CHAIR

Medical School, University of Crete

Frequently Asked Questions

Who can join the NCT07258875 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Thoracic Surgery With One-lung Ventilation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07258875 currently recruiting?

Yes, NCT07258875 is actively recruiting participants. Contact the research team at bogas.alexandros@gmail.com for enrollment information.

Where is the NCT07258875 trial being conducted?

This trial is being conducted at Heraklion, Greece.

Who is sponsoring the NCT07258875 clinical trial?

NCT07258875 is sponsored by University of Crete. The principal investigator is Alexandra Papaioannou, Professor of Anaesthesiology at Medical School, University of Crete. The trial plans to enroll 230 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology